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PHypertrophic Cardiomyopathy
ulticenter Study of the Efficacy
nd Safety of Disopyramide in
bstructive Hypertrophic Cardiomyopathy
ark V. Sherrid, MD, FACC,* Ivan Barac, MD,* William J. McKenna, MD, FACC,†
erry M. Elliott, MD, FACC,† Shaughan Dickie, DCR,† Lidia Chojnowska, MD, PHD,‡
usan Casey, RN,§ Barry J. Maron, MD, FACC§
ew York, New York; London, United Kingdom; Warsaw, Poland; and Minneapolis, Minnesota
OBJECTIVES In this study we assessed the long-term efficacy and safety of disopyramide for patients with
obstructive hypertrophic cardiomyopathy (HCM).
BACKGROUND It has been reported that disopyramide may reduce left ventricular outflow gradient and
improve symptoms in patients with HCM. However, long-term efficacy and safety of
disopyramide has not been shown in a large cohort.
METHODS Clinical and echocardiographic data were evaluated in 118 obstructive HCM patients treated
with disopyramide at 4 HCM treatment centers. Mortality in the disopyramide-treated
patients was compared with 373 obstructive HCM patients not treated with disopyramide.
RESULTS Patients were followed with disopyramide for 3.1  2.6 years; dose 432  181 mg/day (97%
also received beta-blockers). Seventy-eight patients (66%) were maintained with disopyr-
amide without the necessity for major non-pharmacologic intervention with surgical
myectomy, alcohol ablation, or pacing; outflow gradient at rest decreased from 75  33 to 40
 32 mm Hg (p  0.0001) and mean New York Heart Association functional class from 2.3
 0.7 to 1.7  0.6 (p  0.0001). Forty other patients (34%) could not be satisfactorily
managed with disopyramide and required major invasive interventions because of inadequate
symptom and gradient control or vagolytic side effects. All-cause annual cardiac death rate
between disopyramide and non–disopyramide-treated patients did not differ significantly,
1.4% versus 2.6%/year (p  0.07). There was also no difference in sudden death rate,
1.0%/year versus 1.8%/year (p  0.08).
CONCLUSIONS Two-thirds of obstructed HCM patients treated with disopyramide could be managed
medically with amelioration of symptoms and about 50% reduction in subaortic gradient over
3 years. Disopyramide therapy does not appear to be proarrhythmic in HCM and should
be considered before proceeding to surgical myectomy or alternate strategies. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.012Cardiol 2005;45:1251–8) © 2005 by the American College of Cardiology Foundation
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fynamic obstruction to left ventricular (LV) outflow due to
ystolic anterior motion of the mitral valve occurs at rest in
0% to 25% of patients with hypertrophic cardiomyopathy
HCM), and is associated with exercise intolerance due to
yspnea or angina, and with cardiovascular mortality (1–6).
raditionally, negative inotropic drugs represent the first-
ine treatment for symptomatic patients with obstructive
CM. Beta-blockers, often administered first, may improve
ymptoms, but generally do not reduce outflow gradient at
est (7–12). Verapamil has only a modest effect on outflow
radient and should be avoided in patients with particularly
arked obstruction associated with severe symptoms
13,14).
From the *St. Luke’s-Roosevelt Hospital Center, Columbia University, College of
hysicians and Surgeons, New York, New York; †St. George’s Hospital Medical
chool, London, United Kingdom; ‡National Institute of Cardiology, Warsaw,
oland; and the §Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute
oundation, Minneapolis, Minnesota. This work was supported by a grant from Mr.
rthur Frankel.v
Manuscript received June 23, 2004; revised manuscript received December 12,
004, accepted January 4, 2005.Disopyramide, a type I antiarrhythmic drug, has consider-
ble negative inotropic effects and represents a potential alter-
ative drug regimen for obstructive HCM (2,12,15–25). How-
ver, the efficacy of disopyramide in ameliorating outflow
radient and heart failure symptoms has been reported only in
elatively small short-term studies (16–25). Furthermore, de-
ermining the safety of disopyramide is particularly important,
iven the theoretic potential for proarrhythmia in this clinical
etting (26) and recognition that the natural history of HCM
ay be complicated by malignant ventricular arrhythmias and
udden death (3,5,27,28). Therefore, in this study it is timely to
eport the clinical course of 118 patients with obstructive
CM treated with oral disopyramide.
ETHODS
atient selection. The study included all patients with
bstructive HCM consecutively treated at four HCM cen-
ers from 1990 to 1999. These institutions maintain data-
ases of all HCM patients evaluated, with regular periodic
ollow-up by either clinic visit or annual telephone inter-
iews or questionnaires. In the 10-year time period there
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Disopyramide in Hypertrophic Cardiomyopathy April 19, 2005:1251–8ere 1,529 patients treated at the four participating centers.
f these patients, 491 (32%) had outflow obstruction at rest
gradient 30 mm Hg) and 118 (24%) were treated with
isopyramide. The decision to initiate disopyramide for any
ndividual patient was made by the treating physician at the
espective HCM center. This was an integrated judgment
ased on symptoms, echocardiographic findings, and the
atient response to previously administered cardioactive
rugs (2,12). All patients enrolled at participating U.S.
nstitutions consented to the use of their medical informa-
ion for research purposes.
Follow-up began at the initial evaluation when patients
resented for the first time to the respective HCM center.
ata were collected about symptoms, gradient, and known risk
actors for HCM mortality (3,5,27,28). Disopyramide con-
rolled release was routinely initiated in a dose of 200 or 250
g twice a day. Local practice patterns determined whether
atients were admitted to the hospital for this purpose. In the
.S. centers and in Poland, disopyramide was initiated during
two-day hospitalization with electrocardiographic (ECG)
onitoring (29). In the United Kingdom, disopyramide was
nitially administered in an outpatient setting (30). If symp-
oms did not improve, the dose was increased by increments of
00 mg per day at 2-week intervals, up to a maximum tolerated
ose of usually 600 mg/day. Electrocardiograms were per-
ormed on all clinic visits during disopyramide therapy to
onitor QT duration (3).
The most recent evaluation was performed by 2002. At
hat time in disopyramide-treated patients we recorded New
ork Heart Association (NYHA) functional class and the
ast echocardiographically measured outflow gradient per-
ormed while patients took medication. If patients under-
ent a major invasive non-pharmacologic intervention (e.g.,
urgical septal myectomy, alcohol septal ablation, or dual-
hamber pacing), the last NYHA functional class and
radient measured before intervention was selected to assure
hat any change in symptoms or magnitude of obstruction
ould be attributed to a drug effect.
For the survival analyses, we compared mortality in the
isopyramide-treated patients with all other 373 obstructed
CM patients treated at the same centers without diso-
yramide. Annual death rates were compared in the
isopyramide-treated and non–disopyramide-treated groups.
haracteristics of the two patient groups are shown in Table 1.
Mortality was classified as non-cardiac, non-sudden car-
iac, and sudden cardiac death. Sudden cardiac death was
Abbreviations and Acronyms
Diso  disopyramide
ECG  electrocardiogram/electrocardiographic
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
NYHA  New York Heart Association
SAM  systolic anterior motionefined as sudden collapse occurring1 h from the onset of cymptoms in patients without previous severe heart failure-
elated symptoms (including those patients successfully
esuscitated from cardiac arrest). Non-sudden cardiac
eaths occurred in the context of progressive dyspnea and
xercise intolerance, often necessitating hospitalization. Pa-
ients requiring heart transplantation for severe progressive
eart failure with LV systolic dysfunction were classified as
on-sudden cardiac deaths. All-cause cardiac deaths were
he sum of the sudden cardiac deaths plus the non-sudden
ardiac deaths. In this study we did not attempt to classify
hether a given cardiac death was due to HCM.
chocardiography. Hypertrophic cardiomyopathy was di-
gnosed on the basis of two-dimensional echocardiographic
emonstration of a hypertrophied (wall thickness 15 mm)
nd non-dilated LV in the absence of another cardiac or
ystemic disease capable of producing the magnitude of
ypertrophy evident (3,5). Maximum LV wall thickness was
ssessed from the two-dimensional echocardiogram as pre-
iously described (31). Continuous-wave Doppler was used
o measure LV outflow gradient (32). Left ventricular
utflow obstruction was defined as a peak instantaneous
radient under basal (resting) conditions 30 mm Hg
ttributable to systolic anterior motion (SAM) of the mitral
alve.
tatistics. Paired and unpaired Student t tests were used to
able 1. Baseline Characteristics and Treatments in the
isopyramide- and Non–Disopyramide-Treated Patients
umber of patients 118 373 —
ge at initial evaluation (yrs) 47  20 43  21 0.1
uration of follow-up (yrs) 4.2  2.9 6.5  5.2 0.001
ge at last evaluation (yrs) 51  20 50  21 0.7
ale gender (%) 51 53 0.8
YHA functional class at
initial evaluation
2.3  0.7 1.9  0.8 0.002
yncope or pre-syncope (%) 47 26 0.001
yspnea (%) 82 60 0.001
SVT (%) 18 17 0.7
amily history of SCD (%) 15 15 0.9
F at initial evaluation (%)* 20 18 0.7
F during follow-up (%)* 14 17 0.3
V outflow gradient (mm Hg) 74  35 62  32 0.002
ax LV thickness (mm) 21.9  5.5 23.7  6.4 0.02
oronary stenosis 70% (%) 7 2 0.02
eta-blocker (%) 98 70 0.001
alcium channel blocker (%) 32 27 0.2
miodarone (%) 10 30 0.001
eptal myectomy (%) 19 9 0.01
lcohol septal ablation (%) 9 9 1
DD pacemaker (%)† 11 14 0.4
ll interventions combined (%) 34 28 0.2
CD (%)‡ 5 2 0.3
troke during follow-up (%) 3 2 0.6§
Clinically overt atrial fibrillation requiring treatment; †one additional patient had
symptomatic intermittent type II second-degree AV block nine years after beginning
isopyramide; a pacemaker was implanted and disopyramide continued; ‡no appro-
riate ICD shocks at time of follow-up in either group; §Fisher exact test.
AF  atrial fibrillation; AV  atrioventricular; DDD  dual chamber; ICD 
mplantable cardioverter-defibrillator; LV  left ventricular; Max  maximum;
SVT  nonsustained ventricular tachycardia; NYHA  New York Heart Associ-
tion; SCD  sudden cardiac death.ompare continuous variables. For categorical variables we
u
o
i
p
p
d
w
s
B
c
s
a
c
s
i
b
w
C
C
R
B
s
w
(
w
H
c
w
s
d
s
p
t
r
s
p
C
d
8
e
2
D
y
2
c
t
r
c
E
d
a
1
r
P
t
s
n
t
3
d
m
o

0
d
I
4
P
t
r
t
p
d
a
a
m
I
s
t
o
g
H
h
n
m
i
s
2
i
e
0
v
n
t
H
v

4


S
t
i
o
1253JACC Vol. 45, No. 8, 2005 Sherrid et al.
April 19, 2005:1251–8 Disopyramide in Hypertrophic Cardiomyopathysed chi-square tests when all cell expectations were 5;
therwise, Fisher exact tests were used. Annualized mortal-
ty rates, beginning after initial evaluation at each partici-
ating HCM treatment center were calculated by the
erson-year method as the number of patients who died
ivided by the years of follow-up. Kaplan-Meier estimates
ere used to model survival rates for all-cause cardiac,
udden death, and total mortality. The Wilcoxon (Gehan-
reslow) test compared survival rates between groups.
Hazard ratios for death while taking disopyramide were
alculated from proportional hazard regression models as-
uming constant hazard rate. Adjusted hazard ratios for
ll-cause cardiac death while taking disopyramide were
alculated from proportional hazard regression models as-
uming constant hazard rate, entering as covariates age at
nitial evaluation, treatments with surgical septal myectomy,
eta-blockers, calcium channel blockers, and amiodarone as
ell as maximum LV wall thickness. SPSS 10.1 (SPSS Inc.,
hicago, Illinois) and SAS 8.2 software (SAS Institute Inc.,
ary, North Carolina) were used for statistical analyses.
ESULTS
aseline characteristics. At initial evaluation the 118
tudy patients treated with disopyramide at four centers
ere 47  20 years of age (range 1 month to 94 years); 60
51%) were male. Left ventricular outflow gradient at rest
as 74  35 mm Hg (range 30 to 185 mm Hg). New York
eart Association functional class was 2.3  0.7; 14 (12%)
urrently had normal exercise tolerance in class I, 59 (50%)
ere mildly symptomatic in class II, and 45 (38%) were
everely symptomatic in classes III and IV. Exertional
yspnea and syncope or pre-syncope were the most frequent
ymptoms occurring in 97 (82%) and 55 (47%) of the
atients, respectively. Disopyramide was administered to
he 14 patients in NYHA functional class I because of high
esting gradients associated with episodes of impaired con-
ciousness (including syncope in 8 patients) judged to be
robably due to outflow obstruction.
linical course of disopyramide patients. Of the 118
isopyramide patients, 108 (92%) began with disopyramide
 17 months (range 0.1 to 82 months) after initial
valuation, whereas 10 (8%) had started with disopyramide
8  36 months (range 2 to 100 months) previously.
uration of follow-up from initial evaluation was 4.2  2.9
ears during which patients received disopyramide for 3.1
.6 years (range 0.2 to 18 years). Clinical follow-up was
omplete in all 118 patients in the disopyramide group
hrough either clinic visit or phone interview.
Before the initial evaluation 70 (59%) patients had
eceived beta-blockers, 35 (30%) had received calcium
hannel blockers, and 11 (9%) had received a trial of both.
leven (9%) had received another anti-arrhythmic besides
isopyramide before initial evaluation. Highest dose of
dministered disopyramide was 432  181 mg/day (range d50 to 900 mg/day). In addition, 115 (97%) patients
eceived a beta-blocker during follow-up on disopyramide.
atients taking disopyramide without major interven-
ion. Of the 118 disopyramide patients, 78 (66%) were
uccessfully managed medically with disopyramide and did
ot require major interventions (e.g., surgical septal myec-
omy, alcohol septal ablation, or dual-chamber pacing) over
.3 2.7 years. In patients who were treated medically with
isopyramide and a beta-blocker, and who did not require a
ajor invasive intervention during follow-up, average peak
utflow gradient decreased substantially from 75 33 to 40
32 mm Hg (p  0.0001) (Fig. 1).
Mean NYHA functional class score decreased from 2.3
.7 to 1.7  0.6 (p  0.0001) (Fig. 2). At initial evaluation
istribution of NYHA functional class was I  9; II  40;
II/IV  29, and at follow-up distribution was I  29; II 
2, III/IV  7 (p  0.001).
atients requiring non-pharmacologic major interven-
ions. The other 40 disopyramide-treated patients (34%)
equired interventions 2.0  2.1 years after beginning drug
herapy because of both inadequate symptom control and
ersistent gradients 50 mm Hg (n  29), or because of
rug intolerance (n  8) or withdrawal due to initiation of
miodarone (n  3). Of the eight patients with disopyr-
mide intolerance, five had the drug terminated due to dry
outh and three because of symptoms related to prostatism.
nterventions were 22 surgical septal myectomies, 10 alcohol
eptal ablations, and 8 dual-chamber pacemakers. In pa-
ients who required an invasive intervention to control
utflow gradient and heart failure symptoms, average peak
radient decreased modestly from 73  35 to 63  31 mm
g (p  0.05) (Fig. 1, right panel). These patients had
igher gradients while taking disopyramide than did those
ot requiring intervention, 63  31 mm Hg versus 40  32
m Hg (p  0.001) (Fig. 1). In these patients there was no
mprovement in NYHA functional class when comparing
ymptoms before and after disopyramide, 2.3  0.7 versus
.3  0.6 (p  0.6) (Fig. 2). Those patients requiring
nterventions had a higher NYHA functional class at last
valuation than did those not requiring intervention, 2.3 
.6 vs. 1.7  0.6 (p  0.0001).
Disopyramide patients treated medically without inter-
ention and those who required invasive intervention did
ot differ significantly with regard to baseline characteris-
ics: outflow gradient 72  35 mm Hg versus 78  38 mm
g (p  0.4); maximal LV wall thickness 21.1  5 mm
ersus 23.1 6 mm (p 0.08); NYHA functional class, 2.3
0.7 versus 2.3  0.7 (p  0.9); age, 48  20 years versus
4  20 years (p  0.2); gender 44% versus 55% female (p
0.24); disopyramide dose 425  169 mg/day versus 445
201 mg/day (p  0.6).
udden deaths in disopyramide-treated patients. Over
he follow-up period there were four sudden cardiac deaths
n patients who were taking disopyramide at the time. One
ther death occurred nine months after withdrawal of
isopyramide while the patient was taking a beta-blocker.
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Disopyramide in Hypertrophic Cardiomyopathy April 19, 2005:1251–8he four deaths occurred at 46  13 years of age (range 27
o 55 years), 54 43 months (range 2.5 to 98 months) after
isopyramide was initiated. Annual sudden death rate while
ctually taking disopyramide was 0.8%/year. By intention-
o-treat principle annual sudden death rate in patients
egun with disopyramide was 1.0%/year.
Patients with and without sudden death while actually
igure 1. (Left) Response of peak instantaneous systolic left ventricular
ithout the requirement for invasive non-pharmacologic intervention (such
epicted are the outflow gradients of 62 patients who had serial echocar
equired invasive intervention because of inadequate relief of heart failure
f 33 patients who had serial echocardiographic assessments. All gradient
igure 2. Response of New York Heart Association (NYHA) functional
lass in patients treated medically with disopyramide (Diso) but without
equirement for invasive non-pharmacologic intervention (such as surgical
eptal myectomy, alcohol septal ablation, or dual-chamber pacing), and in
atients with failed maximum medical therapy who ultimately did require
uch interventions.
Aaking disopyramide did not differ with respect to age, 41 15
ears versus 47  20 years (p  0.5); NYHA functional class,
.0  0.8 versus 2.3  0.7 (p  0.4); gradient, 88  35 mm
g versus 74  35 mm Hg (p  0.4); or disopyramide dose,
17  225 mg versus 424  171 mg (p  0.4).
urvival analysis. There was no significant difference the
n annualized all-cause cardiac death rate, 1.4% versus
.6%/year (p  0.07), between the 118 disopyramide-
reated and 373 non–disopyramide-treated HCM patients.
here was also no difference in the annualized sudden death
ate, 1.0%/year versus 1.8%/year (p  0.08) (Table 2, Figs.
and 4). There also was no significant difference in
nnualized total mortality between the disopyramide-
reated and non–disopyramide-treated patients, 2.8% versus
w tract gradient in patients treated medically with disopyramide (Diso)
rgical septal myectomy, alcohol septal ablation, or dual-chamber pacing).
aphic assessments with continuous-wave Doppler. (Right) Patients who
oms and persistent outflow gradients. Depicted are the outflow gradients
urements in this group were performed before intervention.
able 2. Annualized Death Rates in Disopyramide- and Non–
isopyramide-Treated Patients
Mode of Death Disopyramide
Non-
Disopyramide p Value
on-cardiac 1.4% 1.2% 0.75
on-sudden cardiac 0.4% 0.9% 0.54
udden cardiac 1.0% 1.8% 0.08
ll-cause cardiac 1.4% 2.6% 0.07outflo
as su
diogrll deaths 2.8% 3.8% 0.1
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April 19, 2005:1251–8 Disopyramide in Hypertrophic Cardiomyopathy.8%/year (p 0.1). Hazard ratio for all-cause cardiac death
hile taking disopyramide was 0.55 (confidence interval 
.24 to 1.20; p 0.13).
There was no difference in the frequency of atrial fibril-
ation and stroke in the two groups (Table 1). There were
o appropriate discharges of implantable cardioverter-
efibrillators in either the disopyramide or control groups,
igure 3. Kaplan-Meier survival plot for all-cause cardiac mortality in d
ypertrophic cardiomyopathy.igure 4. Kaplan-Meier survival plot for sudden cardiac death in disopyra
ypertrophic cardiomyopathy.ut two deaths related to surgical septal myectomy occurred
n the non–disopyramide-treated patients.
With multivariate analysis that included treatment with
urgical septal myectomy, beta-blockers, calcium channel
lockers or amiodarone, maximum LV wall thickness, and
ge, the hazard ratio for all-cause cardiac death on disopyr-
mide still showed no significant difference between the
ramide-treated and non–disopyramide-treated patients with obstructiveisopymide-treated and non–disopyramide-treated patients with obstructive
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Disopyramide in Hypertrophic Cardiomyopathy April 19, 2005:1251–8isopyramide and non-disopyramide comparison group,
ith a hazard ratio of 0.72 (confidence interval  0.32 to
.64; p  0.43).
ISCUSSION
rug benefit. The present study substantiates that phar-
acologic therapy in obstructive HCM can be successful in
ontrolling heart failure symptoms in most patients, and
hat disopyramide (in combination with a beta-blocker) has
role in the maximal medical management of this disease by
irtue of sustained reduction of outflow gradient and dis-
bling symptoms in two-thirds of study patients. Average
eak LV outflow gradient at rest was reduced after three
ears by almost 50% and generally below the threshold at
hich surgery would be considered. Limiting symptoms
mproved in parallel, with the mean NYHA functional class
ecreasing from 2.3 to 1.7. Indeed, two-thirds of our
atients have had gratifying results and did not require
nvasive intervention, largely because of disopyramide, for
ore than three years.
The remaining one-third of our patients were non-
esponders and accrued no sustained pharmacologic benefit.
isopyramide was ineffective in controlling symptoms and
radient, or vagolytic side effects required discontinuation of
he drug. In these latter treatment failures a major non-
harmacologic intervention (e.g., surgical septal myectomy,
lcohol septal ablation, or dual-chamber pacing) was re-
uired an average of two years after disopyramide was
nitiated.
ortality analysis. Disopyramide-treated HCM patients
ere compared with a group of obstructive HCM patients
ith a similar degree of outflow obstruction treated without
isopyramide at the four centers. There was no difference in
nnualized all-cause cardiac death rates, 1.4%/year versus
.6%/year, between disopyramide-treated and the non–
isopyramide-treated patients, and also no difference in
udden cardiac death rates in these two groups, 1.0%/year
ersus 1.8%/year. This analysis substantiates that disopyr-
mide is not proarrhythmic in HCM and does not increase
he risk for sudden or other cardiac death. The lack of a
ignificant difference between the disopyramide and com-
arison groups persisted after multivariate analysis, which
ncluded as covariates surgical myectomy, drug therapy with
eta-blockers, calcium channel blockers, and amiodarone,
aximum LV wall thickness, and age.
echanism of disopyramide benefit. The mechanism of
isopyramide benefit for outflow gradient and symptom
elief in HCM is likely attributable to its negative inotropic
ffects (15,20,33). After disopyramide, LV ejection fraction
as been reported to decrease by 5% to 10% (23,34). The
enefit for reduction of SAM and gradient appears to be
ediated by a decrease in LV ejection acceleration (20). By
ecreasing ejection velocities early in systole, negative ino-
ropic drugs decrease hydrodynamic forces on the mitral
alve, thus delaying or preventing SAM. Drag, the pushing sorce of flow, appears to be the predominant hydrodynamic
orce on the mitral leaflets (4,35–37). Because this hydro-
ynamic force on the leaflet is proportional to the square of
he velocity, even small changes in acceleration and velocity
an lead to large decreases in force (20,37). Lowering
radients may benefit symptoms by a variety of mechanisms
ncluding improvement in oxygen supply-demand mis-
atch, LV relaxation by relieving systolic load, and LV
jection flow (18,23,38–41).
ole of disopyramide for symptomatic obstructive HCM.
ymptomatic HCM patients with outflow obstruction are
enerally treated initially with a beta-blocker, which may
lunt gradients that are physiologically provoked with ex-
rcise and thereby improve symptoms. However, beta-
locking therapy is not expected to reduce resting gradient
7–12) and may not control symptoms satisfactorily in some
atients. For those patients with refractory obstruction and
ymptoms after a trial with beta-blockers, alternative drugs
re required. There has been diversity in the selection of the
econd drug trial. The most frequent approach is to substi-
ute verapamil for beta-blocker (13,42–44). Others support
n alternate strategy of combining disopyramide with a
eta-blocker (2,12,20,45).
Previous studies using verapamil in symptomatic ob-
tructed HCM patients have showed relatively frequent
ardiac hemodynamic and electrophysiologic side effects
arly after institution of the drug (13,14,42,44). Patients
ho developed severe pulmonary congestion usually had
ubstantial pre-existing heart failure symptoms, high pul-
onary wedge pressures, and LV outflow gradients exceed-
ng 50 mm Hg (14,42). This is a potentially important
imitation given the intuition to administer verapamil to
edically refractory patients who would otherwise be can-
idates for septal myectomy or other interventions. There-
ore, some investigators reserve verapamil for those patients
ith mild or moderate symptoms and no or modest outflow
radients (1,2,12,45).
The present study of disopyramide appears to contrast
ith the experience using verapamil in obstructive HCM
13,14,42). In the first six months of disopyramide therapy
nly one patient developed worsening heart failure appar-
ntly due to disease progression. This low incidence is likely
ttributable to the recognition that disopyramide is not
ssociated with vasodilation (16,18). Furthermore, our only
xperience with bradycardia or atrio-ventricular block (not
ncommon with verapamil) was in a patient after nine years
f disopyramide treatment. The principal side effects of
isopyramide were the vagolytic effects of dry mouth and
rostatism that caused drug discontinuation relatively infre-
uently in 7% of our patients. Disopyramide generally does
ot cause hepatic, renal, or central nervous system toxicity,
nd none was observed in the present study.
Kimball et al. (21) noted a modest 5% increase in
orrected QT interval from 423 to 443 ms in HCM patients
reated with disopyramide, which was similar to that ob-
erved previously in normal subjects (46). In the present
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April 19, 2005:1251–8 Disopyramide in Hypertrophic Cardiomyopathytudy, ECG surveillance was routinely performed on all
linic follow-up visits as recommended (3); marked QT
nterval prolongation was not identified and the drug was
ot discontinued in any patient for this reason.
tudy limitations. Despite the retrospective design of this
tudy, we believe that our observations regarding disopyr-
mide efficacy and safety can be regarded as representative.
or example, the lack of significant difference in mortality
etween the disopyramide and non-disopyramide patients is
ubstantiated for a number of reasons. First, disopyramide-
reated patients had higher outflow gradients and were more
ymptomatic than the comparison group of HCM patients
nd, therefore, could be expected to have less favorable
utcome. Second, disopyramide and non-disopyramide pa-
ients were similar with respect to their risk factors for
CM-related mortality. Third, the lack of difference in
ll-cause cardiac mortality with disopyramide persisted after
ultivariate analysis that included other treatment modali-
ies as covariates.
Of note, only about 5% of our patients could not tolerate
isopyramide and required premature termination of the drug.
owever, it is important to emphasize that disopyramide
hould not be administered to HCMpatients in certain clinical
cenarios, such as when prostatism is present. Other antiar-
hythmic drugs such as amiodarone or sotolol should not be
dministered in association with disopyramide in order to
void possible proarrhythmia. If such agents are to be used,
isopyramide should be discontinued. Because of its impaired
limination in patients with renal insufficiency, disopyramide
hould be administered in reduced dosage and with careful
onitoring in such patients (17). Because there was no direct
omparison of disopyramide with other cardioactive agents in
his study design, we cannot conclude from our data that one
harmacologic agent was superior to another in the treatment
f symptoms in HCM.
onclusions. Disopyramide has a useful role in the ther-
peutic armamentarium for obstructive HCM by virtue of
educing LV outflow tract gradients and controlling symp-
oms in the majority of patients. Disopyramide does not
ppear to be proarrhythmic in HCM. Administration of
isopyramide, in combination with a beta-blocker, should
e considered in patients with obstructive HCM before
roceeding to invasive interventions.
eprint requests and correspondence: Dr. Mark V. Sherrid, St.
uke’s-Roosevelt Hospital Center, College of Physicians and
urgeons, Columbia University, 1000 10th Avenue, 3B-30, New
ork, New York 10019. E-mail: msherrid@chpnet.org.
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